Loading...
•
Dec 31, 2024
Evolus Q4 2024 Earnings Report
Evolus reported record Q4 2024 revenue with continued strong growth.
Key Takeaways
Evolus achieved a record fourth-quarter revenue of $79.0 million, representing a 30% increase year-over-year. The company reported a GAAP operating loss of $2.3 million, with a positive non-GAAP operating income of $6.7 million. Cash and cash equivalents increased to $87.0 million, reflecting strong sales growth and prudent expense management.
Q4 2024 revenue grew 30% year-over-year to $79.0 million.
Non-GAAP operating income reached $6.7 million, showing profitability improvements.
Cash and cash equivalents increased to $87.0 million.
Continued expansion of Jeuveau and launch preparations for Evolysse in 2025.
Forward Guidance
Evolus expects strong revenue growth in 2025, with new product launches contributing to expansion.
Positive Outlook
- 2025 revenue guidance of $345M to $355M, a 30-33% increase.
- Evolysse and Estyme products expected to contribute 8-10% of revenue.
- Company expects to achieve positive non-GAAP operating income in 2025.
- Continued expansion of Jeuveau in the U.S. and internationally.
- Projected total revenue of at least $700M by 2028 with 20% operating margin.
Challenges Ahead
- Investments in Evolysse launch may weigh on short-term profitability.
- Non-GAAP operating income concentration expected in Q4 2025.
- Market adoption of new products remains uncertain.
- Competition in the aesthetic medicine space continues to increase.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...